# EDGAR Filing Document

**Accession Number:** 0001940272
**File Stem:** 0001104659-25-078851
**Filing Date:** 2025-8
**Character Count:** 12711
**Document Hash:** 73cf3e1fa1f43c0559aea552ab98dc83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-078851.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001104659-25-078851

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioAge Labs, Inc.
- **CENTRAL INDEX KEY:** 0001709941
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474721157
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94634
- **FILM NUMBER:** 251221987

**BUSINESS ADDRESS:**
- **STREET 1:** 5885 HOLLIS STREET
- **STREET 2:** SUITE 370
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** 510-806-1445

**MAIL ADDRESS:**
- **STREET 1:** 5885 HOLLIS STREET
- **STREET 2:** SUITE 370
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADAR1 Capital Management, LLC
- **CENTRAL INDEX KEY:** 0001940272

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 3503 WILD CHERRY DRIVE
- **STREET 2:** BUILDING 9
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738
- **BUSINESS PHONE:** 512-254-3790

**MAIL ADDRESS:**
- **STREET 1:** 3503 WILD CHERRY DRIVE
- **STREET 2:** BUILDING 9
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78738

## Ex-99.(A)

**EXHIBIT A**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of common stock, par value $0.00001 per share of BioAge Labs, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of August 14, 2025.

---

| |
|:---|
| **ADAR1 CAPITAL MANAGEMENT, LLC** |
| /s/ Daniel Schneeberger |
| Daniel Schneeberger |
| Manager |
| **ADAR1 CAPITAL MANAGEMENT GP, LLC** |
| /s/ Daniel Schneeberger |
| Daniel Schneeberger |
| Manager |
| /s/ Daniel Schneeberger |
| **Daniel Schneeberger**, in his individual capacity |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** BioAge Labs, Inc.

**Title of Class of Securities:** Common Stock, par value $0.00001 per share

**CUSIP Number:** 09077V100

**Date of Event Which Requires Filing of this Statement:** 06/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [x] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>ADAR1 Capital Management, LLC | Names of Reporting Persons<br>ADAR1 Capital Management, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>TX | Citizenship or Place of Organization<br>TX |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1937123.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1937123.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1937123.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1937123.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.4% | Percent of Class Represented by Amount in Row (9)<br>5.4% |
| 12. | Type of Reporting Person (See Instructions)<br>IA, OO | Type of Reporting Person (See Instructions)<br>IA, OO |

**Comment for Type of Reporting Person:** Includes (i) 1,662,162 shares of common stock, par value $0.00001 per share ("Common Stock") held by ADAR1 Partners, LP and (ii) 274,961 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC as of June 30,2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.

Based on 35,850,037 shares of Common Stock of BioAge Labs, Inc. (the "Issuer") outstanding as of June 30, 2025, reported in the Issuer's 10-Q, filed with the SEC on August 6, 2025.

---

| 1. | Names of Reporting Persons<br>Daniel Schneeberger | Names of Reporting Persons<br>Daniel Schneeberger |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>V8 | Citizenship or Place of Organization<br>V8 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1937123.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1937123.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1937123.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1937123.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.4% | Percent of Class Represented by Amount in Row (9)<br>5.4% |
| 12. | Type of Reporting Person (See Instructions)<br>HC, IN | Type of Reporting Person (See Instructions)<br>HC, IN |

**Comment for Type of Reporting Person:** Includes (i) 1,662,162 shares of common stock, par value $0.00001 per share ("Common Stock") held by ADAR1 Partners, LP and (ii) 274,961 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC as of June 30, 2025. As the manager of ADAR1 Capital Management, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.

Based on 35,850,037 shares of Common Stock of BioAge Labs, Inc. (the "Issuer") outstanding as of June 30, 2025 reported in the Issuer's 10-Q, filed with the SEC on August 6, 2025.

---

**Item 1(a). Name of Issuer:**
BioAge Labs, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
5885 Hollis Street Suite 370 Emeryville, CA, 94608

**Item 2(a). Name of Person Filing:**
This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"):

(i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); and

(ii) Daniel Schneeberger ("Mr. Schneeberger").

**Item 2(b). Address of Principal Business Office:**
The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

**Item 2(c). Citizenship:**
(i) ADAR1 Capital Management is a Texas limited liability company; and

(ii) Mr. Schneeberger is a citizen of Switzerland.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.00001 per share

**Item 2(e). CUSIP Number:**
09077V100

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [x] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [x] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

**(b) Percent of class:**

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

**(ii) Shared power to vote or to direct the vote:**

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

**(iii) Sole power to dispose or to direct the disposition of:**

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

**(iv) Shared power to dispose or to direct the disposition of:**

The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**ADAR1 Capital Management, LLC**

**Date:** 08/14/2025

**By:** /s/ Daniel Schneeberger

**Name & Title:** Daniel Schneeberger, Manager

**Daniel Schneeberger**

**Date:** 08/14/2025

**By:** /s/ Daniel Schneeberger

**Name & Title:** Daniel Schneeberger, in his individual capacity